Credit Suisse Reiterates a Hold Rating on PRA Health Sciences

By Ryan Adsit

In a report released yesterday, Erin Wilson from Credit Suisse reiterated a Hold rating on PRA Health Sciences (NASDAQ: PRAH), with a price target of $50. The company’s shares opened today at $54.

Wilson noted:

“We are lowering our 2016 EPS to $2.47 (from $2.48), still at the higher end of its upped guidance range ($2.45-$2.48), to reflect the miss. Our PT remains $50.”

According to, Wilson is a 4-star analyst with an average return of 6.2% and a 53.2% success rate. Wilson covers the Healthcare sector, focusing on stocks such as Dentsply International Inc., Quest Diagnostics Inc., and Phibro Animal Health.

PRA Health Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $57.

Based on PRA Health Sciences’ latest earnings report from June 30, the company posted quarterly revenue of $455.8M and quarterly net profit of $38.67M. In comparison, last year the company earned revenue of $403.5M and had a net profit of $23.66M.

Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is negative on the stock.

PRA Health Sciences, Inc. is a contract research organization, which engages in the provision of outsourced clinical development services to the biotechnology and pharmaceutical industries. It includes data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. The company was founded in 1976 and is headquartered in Raleigh, NC.